Literature DB >> 10507601

Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment.

J G Clark1, D K Madtes, T R Martin, R C Hackman, A L Farrand, S W Crawford.   

Abstract

OBJECTIVE: To determine whether idiopathic pneumonia syndrome (IPS), a form of noninfectious lung injury that follows bone marrow transplantation, is associated with cytokine activation and increased susceptibility to lipopolysaccharide (LPS).
DESIGN: Case series.
SETTING: Tertiary referral center for marrow transplantation. PATIENTS: Recipients with biopsy-confirmed IPS; normal volunteers and marrow transplant recipients without IPS were analyzed as controls.
MEASUREMENTS AND MAIN RESULTS: Levels of lymphocyte and macrophage-derived cytokines as well as components of the LPS, LPS-binding protein (LBP), and CD14 system in bronchoalveolar lavage (BAL) fluid were determined. We found evidence of increased vascular permeability (BAL protein) and inflammatory cytokine activation (interleukin-1, interleukin-2, interleukin-6, and tumor necrosis factor-alpha) in patients with IPS. Patients without IPS had BAL fluid cytokine and protein levels that were similar to levels in BAL fluid from normal volunteers. Moreover, components of the LPS amplification system (LBP and soluble CD14) were increased in patients with IPS but not in patients without IPS.
CONCLUSIONS: These results provide direct evidence for proinflammatory cytokine activation in IPS and suggest that these patients might be at increased risk for LPS-mediated injury through the LBP amplification pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507601     DOI: 10.1097/00003246-199909000-00016

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  19 in total

1.  A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.

Authors:  Sabarinath Venniyil Radhakrishnan; Gerhard C Hildebrandt
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

2.  Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials.

Authors:  J W Chien; M Sakai; T A Gooley; H G Schoch; G B McDonald
Journal:  Bone Marrow Transplant       Date:  2009-06-29       Impact factor: 5.483

Review 3.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

4.  Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.

Authors:  Gregory A Yanik; Mary M Horowitz; Daniel J Weisdorf; Brent R Logan; Vincent T Ho; Robert J Soiffer; Shelly L Carter; Juan Wu; John R Wingard; Nancy L Difronzo; James L Ferrara; Sergio Giralt; David K Madtes; Rebecca Drexler; Eric S White; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-07       Impact factor: 5.742

5.  TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521).

Authors:  Gregory A Yanik; Stephan A Grupp; Michael A Pulsipher; John E Levine; Kirk R Schultz; Donna A Wall; Bryan Langholz; Christopher C Dvorak; Keith Alangaden; Rakesh K Goyal; Eric S White; Jennifer M Collura; Micah A Skeens; Saada Eid; Elizabeth M Pierce; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-28       Impact factor: 5.742

Review 6.  Translational research efforts in biomarkers and biology of early transplant-related complications.

Authors:  Sophie Paczesny; Maribel Diaz-Ricart; Enric Carreras; Enrique Carerras; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

7.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

8.  A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome.

Authors:  Gerhard C Hildebrandt; Krystyna M Olkiewicz; Leigh Corrion; Shawn G Clouthier; Elizabeth M Pierce; Chen Liu; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

9.  Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.

Authors:  Sandra Miklos; Gunnar Mueller; Yayi Chang; Abdellatif Bouazzaoui; Elena Spacenko; Thomas E O Schubert; David J Grainger; Ernst Holler; Reinhard Andreesen; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2009-03-14       Impact factor: 2.490

10.  Pulmonary edema and pleural effusion in norepinephrine-stimulated rats--hemodynamic or inflammatory effect?

Authors:  Beate Rassler; Christian Reissig; Wilfried Briest; Andrea Tannapfel; Heinz-Gerd Zimmer
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.